Does ROSUVASTATIN Cause Hyperparathyroidism secondary? 14 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 14 reports of Hyperparathyroidism secondary have been filed in association with ROSUVASTATIN (Rosuvastatin Calcium). This represents 0.0% of all adverse event reports for ROSUVASTATIN.
14
Reports of Hyperparathyroidism secondary with ROSUVASTATIN
0.0%
of all ROSUVASTATIN reports
11
Deaths
12
Hospitalizations
How Dangerous Is Hyperparathyroidism secondary From ROSUVASTATIN?
Of the 14 reports, 11 (78.6%) resulted in death, 12 (85.7%) required hospitalization.
Is Hyperparathyroidism secondary Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ROSUVASTATIN. However, 14 reports have been filed with the FAERS database.
What Other Side Effects Does ROSUVASTATIN Cause?
Myalgia (3,958)
Dyspnoea (2,832)
Pain (2,758)
Drug ineffective (2,347)
Fatigue (2,208)
Rhabdomyolysis (2,173)
Arthralgia (1,879)
Asthma (1,843)
Muscle spasms (1,843)
Pain in extremity (1,686)
What Other Drugs Cause Hyperparathyroidism secondary?
ESOMEPRAZOLE (1,357)
OMEPRAZOLE (1,274)
PANTOPRAZOLE (947)
LANSOPRAZOLE (888)
DEXLANSOPRAZOLE (382)
RABEPRAZOLE (108)
DENOSUMAB (60)
FUROSEMIDE (49)
OMEPRAZOLE\SODIUM BICARBONATE (48)
ESOMEPRAZOLE\NAPROXEN (47)
Which ROSUVASTATIN Alternatives Have Lower Hyperparathyroidism secondary Risk?
ROSUVASTATIN vs ROSUVASTATIN\ROSUVASTATIN
ROSUVASTATIN vs ROTIGOTINE
ROSUVASTATIN vs ROXADUSTAT
ROSUVASTATIN vs ROXICODONE
ROSUVASTATIN vs ROXITHROMYCIN